Application and Impact of Human Dose Projection from Discovery to Early Drug Development

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2020 Jan 4

PMID 31897807

Citations 1

Authors

Dipal Patel

Wenzhan Yang

Maya Lipert

Tian Wu

Affiliations

Soon will be listed here.

Abstract

The application and impact of human dose projection (HDP) has been well recognized in the late drug development phase, with increasing appreciation earlier during discovery and early development. This commentary describes the perspective of pharmaceutical scientists on the evolving application and impact of HDP at various phases from discovery to early development, including lead generation, lead optimization, lead up to candidate nomination, and early drug development. The underlying fundamental concepts and key input parameters for HDP are briefly discussed. A broad overview of phase-specific tools and approaches commonly utilized for human dose projection in the pharmaceutical industry is provided. A discussion of phase-appropriate implementation strategies, associated limitations/assumptions and continuous refinement for HDP from discovery to early development is presented. The authors describe the phase-specific applications of human dose projection to facilitate key assessments and relative impact on decision points.

Citing Articles

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm.

Neary M, Owen A, Olagunju A Clin Infect Dis. 2022; 75(Suppl 4):S490-S497.

PMID: 36410386 PMC: 10200324. DOI: 10.1093/cid/ciac685.

References

DiMasi J, Feldman L, Seckler A, Wilson A . Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010; 87(3):272-7. DOI: 10.1038/clpt.2009.295. View

Zou P, Yu Y, Zheng N, Yang Y, Paholak H, Yu L . Applications of human pharmacokinetic prediction in first-in-human dose estimation. AAPS J. 2012; 14(2):262-81. PMC: 3326168. DOI: 10.1208/s12248-012-9332-y. View

Waring M, Arrowsmith J, Leach A, Leeson P, Mandrell S, Owen R . An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015; 14(7):475-86. DOI: 10.1038/nrd4609. View

Reigner B, Williams P, Patel I, Steimer J, Peck C, van Brummelen P . An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet. 1997; 33(2):142-52. DOI: 10.2165/00003088-199733020-00005. View

Heimbach T, Lakshminarayana S, Hu W, He H . Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J. 2009; 11(3):602-14. PMC: 2758129. DOI: 10.1208/s12248-009-9136-x. View

Hughes J, Rees S, Kalindjian S, Philpott K . Principles of early drug discovery. Br J Pharmacol. 2010; 162(6):1239-49. PMC: 3058157. DOI: 10.1111/j.1476-5381.2010.01127.x. View

Obach R, BAXTER J, Liston T, Silber B, Jones B, Macintyre F . The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997; 283(1):46-58. View

Hosea N, Collard W, Cole S, Maurer T, Fang R, Jones H . Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 2009; 49(5):513-33. DOI: 10.1177/0091270009333209. View

Peach M, Zakharov A, Liu R, Pugliese A, Tawa G, Wallqvist A . Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software. Future Med Chem. 2012; 4(15):1907-32. PMC: 3992830. DOI: 10.4155/fmc.12.150. View

10.

Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

11.

Hallifax D, Foster J, Houston J . Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res. 2010; 27(10):2150-61. DOI: 10.1007/s11095-010-0218-3. View

12.

Obach R . Predicting clearance in humans from in vitro data. Curr Top Med Chem. 2011; 11(4):334-9. DOI: 10.2174/156802611794480873. View

13.

Jones R, Jones H, Rowland M, Gibson C, Yates J, Chien J . PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011; 100(10):4074-89. DOI: 10.1002/jps.22553. View

14.

Howard M, Hill J, Galluppi G, McLean M . Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen. 2010; 13(2):170-87. DOI: 10.2174/138620710790596745. View

15.

Varma M, Obach R, Rotter C, Miller H, Chang G, Steyn S . Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010; 53(3):1098-108. DOI: 10.1021/jm901371v. View

16.

Pidgeon C, Pitlick W . Unique approach to calculation of first-order absorption rate constants from blood or urine data. J Pharmacokinet Biopharm. 1980; 8(2):203-14. DOI: 10.1007/BF01065194. View

17.

Kesisoglou F, Wu Y . Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008; 10(4):516-25. PMC: 2628211. DOI: 10.1208/s12248-008-9061-4. View

18.

Jones H, Gardner I, Watson K . Modelling and PBPK simulation in drug discovery. AAPS J. 2009; 11(1):155-66. PMC: 2664888. DOI: 10.1208/s12248-009-9088-1. View

19.

Rizk M, Zou L, Savic R, Dooley K . Importance of Drug Pharmacokinetics at the Site of Action. Clin Transl Sci. 2017; 10(3):133-142. PMC: 5421734. DOI: 10.1111/cts.12448. View

20.

Gabrielsson J, Fjellstrom O, Ulander J, Rowley M, van der Graaf P . Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr Top Med Chem. 2011; 11(4):404-18. DOI: 10.2174/156802611794480864. View